XML 14 R4.htm IDEA: XBRL DOCUMENT v3.25.2
Consolidated Statements of Income and Comprehensive Income (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Revenues $ 48,561 $ 42,983 $ 99,307 $ 84,910
Cost of products sold 36,960 31,420 74,961 61,877
Gross profit 11,601 11,563 24,346 23,033
Operating expenses:        
Research and development 2,318 1,997 4,722 3,753
Selling, general and administrative 7,027 5,649 13,969 11,300
Total operating expenses 9,345 7,646 18,691 15,053
Operating income 2,256 3,917 5,655 7,980
Other (expense) income:        
Interest and financing expense 992 418 2,024 938
Miscellaneous expense (income) 151 (347) 72 (411)
Total other expense 1,143 71 2,096 527
Income before income taxes 1,113 3,846 3,559 7,453
Income tax provision 243 853 810 1,556
Net income 870 2,993 2,749 5,897
Net income (loss) attributable to non-controlling interest (9) 24 5 37
Net income attributable to Ultralife Corporation 879 2,969 2,744 5,860
Other comprehensive income (loss):        
Foreign currency translation adjustments 875 (3) 1,186 (235)
Comprehensive income attributable to Ultralife Corporation $ 1,754 $ 2,966 $ 3,930 $ 5,625
Net income per share attributable to Ultralife common stockholders – basic (in dollars per share) $ 0.05 $ 0.18 $ 0.17 $ 0.36
Net income per share attributable to Ultralife common stockholders – diluted (in dollars per share) $ 0.05 $ 0.18 $ 0.17 $ 0.35
Weighted average shares outstanding – basic (in shares) 16,635 16,568 16,634 16,482
Potential common shares (in shares) 21 257 37 179
Weighted average shares outstanding - diluted (in shares) 16,656 16,825 16,671 16,661